Monitor EVANGELINE Phase 2 top-line data expected in 4Q26 and IND clearance for MAS/DMD programs in 2H26 as key near-term catalysts. Cash runway into 2027 provides no immediate financing urgency.
Price Chart
Executive Summary
Atossa Therapeutics filed an 8-K on September 18, 2026, to make available an updated corporate investor presentation (Exhibit 99.1). The presentation highlights the company's lead drug candidate (Z)-Endoxifen across oncology (breast cancer) and rare disease (MAS, DMD) programs, reports $26.1M cash and equivalents with no debt at June 30, 2026, and notes EVANGELINE Phase 2 enrollment completed with top-line data anticipated in 4Q26. This is a routine disclosure of existing strategy and financial position with no new material financial data or catalysts.
Key Facts
- $26.1M cash and equivalents at June 30, 2026
- No debt outstanding at June 30, 2026
- Total operating expenses of $8.7M in Q2 2026
- June 2026 registered direct offering raised $4.0M (net)
- Up to $12M additional from Series A and short-term Series B warrants, assuming full cash exercise
- EVANGELINE Phase 2 enrollment completed as of June 30, 2026; top-line data anticipated in 4Q26
- IND clearance in MAS and DMD anticipated in 2H26
- FDA Rare Pediatric Disease designation for both MAS and DMD; Orphan Drug Designation for DMD
- ~800 patients dosed with (Z)-endoxifen to date
Financial Impact
No new financial data or guidance provided; cash position of $26.1M as of June 30, 2026, with $8.7M quarterly operating burn rate
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products
- Relies on capital markets for future funding beyond 2027
- Clinical trial results may not support regulatory approval
- Warrant exercise is optional and may not provide additional capital
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-395694 |
| Document: atos-ex99_1.htm | 0001193125-26-395694 |
| Document: 0001193125-26-395694-index-headers.html | 0001193125-26-395694 |
| Document: 0001193125-26-395694-index.html | 0001193125-26-395694 |
| Document: 0001193125-26-395694.txt | 0001193125-26-395694 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $2.44 | awaiting T+60 | — | $2.45 (+0.41%) |
Sep 29, 2026 27d ago | 8-K | $1.99 | awaiting T+60 | — | $2.45 (+23.12%) |
Sep 18, 2026 5w ago | 8-K | $2.25 | awaiting T+60 | — | $2.45 (+8.89%) |
Aug 7, 2026 11w ago | 8-K | $2.36 | awaiting T+60 | — | $2.45 (+3.81%) |
Aug 7, 2026 11w ago | Press Release | $2.36 | awaiting T+60 | — | $2.45 (+3.81%) |
Jun 12, 2026 19w ago | 424B5 | $2.46 $2.52 | ▼ −2.24% | ▲ +1.03% | $2.45 (+0.41%) |
Apr 16, 2026 27w ago | 8-K | $5.77 $2.40 | ▼ −58.41% | ▼ −65.45% | $2.45 (−57.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers